Amitriptyline

Amitriptyline (3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine) is a first-generation tricyclic antidepressant (TCA) and the second member of the tricyclic class to reach the market, approved by the United States Food and Drug Administration in 1961 for the treatment of major depressive disorder. Originally developed at Merck Sharp and Dohme as a structural analog of imipramine in which the diamine bridge nitrogen is replaced by an exocyclic propylidene chain, amitriptyline inhibits the serotonin transporter (SERT) and norepinephrine transporter (NET) with low-nanomolar affinity for both targets (Ki approximately 3.1 nM for SERT, 19 nM for NET), producing dual monoamine reuptake inhibition that is mechanistically ancestral to the modern selective serotonin-norepinephrine reuptake inhibitors. Amitriptyline is distinguished from the SSRIs and SNRIs, however, by extensive polypharmacology at secondary targets: the compound acts as a potent antagonist at histamine H1 receptors (Ki approximately 1.1 nM), muscarinic acetylcholine receptors (Ki approximately 14 nM), and alpha-1 adrenergic receptors (Ki approximately 24 nM); as a use-dependent blocker of voltage-gated sodium channels through binding at the local anesthetic receptor site; and as an open-channel blocker of NMDA-type glutamate receptors with an IC50 in the low-micromolar range. This composite receptor profile produces the broad clinical utility of amitriptyline but also the anticholinergic, sedative, and cardiovascular adverse-event burden that has driven displacement by narrower-spectrum agents in the primary antidepressant indication.

Despite the decline of tricyclic antidepressant prescribing for depression in the SSRI era, amitriptyline remains one of the most widely prescribed medications worldwide. The World Health Organization lists amitriptyline on its Model List of Essential Medicines. The compound is a first-line treatment for neuropathic pain in multiple international guidelines (NICE, AAN, NeuPSIG), supported by decades of randomized controlled trial evidence in painful diabetic neuropathy, postherpetic neuralgia, and mixed neuropathic pain syndromes. The 2022 OPTION-DM trial, the largest head-to-head crossover neuropathic pain trial ever conducted, demonstrated equivalent analgesic efficacy of amitriptyline, duloxetine, and pregabalin monotherapy in diabetic peripheral neuropathic pain, with combination therapy producing superior analgesia. The 2023 ATLANTIS trial, the largest randomized controlled trial of a tricyclic antidepressant in irritable bowel syndrome, demonstrated that low-dose titrated amitriptyline (10 to 30 mg daily) was superior to placebo as second-line treatment for IBS in primary care across multiple symptom endpoints at 6 months. Amitriptyline is recommended for migraine prophylaxis (NNT approximately 3 to 4 for 50 percent headache frequency reduction) and for fibromyalgia analgesia, and it retains clinical use in tension-type headache, insomnia comorbid with chronic pain, nocturnal enuresis, and selected anxiety disorders.

Pharmacokinetics are dominated by hepatic metabolism through two principal cytochrome P450 pathways: CYP2C19-mediated N-demethylation to the active metabolite nortriptyline (itself a potent and selective NET inhibitor) and CYP2D6-mediated hydroxylation to 10-hydroxymetabolites that are subsequently glucuronidated and renally excreted. Both CYP2C19 and CYP2D6 exhibit clinically significant genetic polymorphism. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published dosing guidelines for amitriptyline indexed to CYP2D6 and CYP2C19 genotype, recommending dose reduction or alternative agent selection in CYP2D6 poor metabolizers and CYP2C19 ultrarapid metabolizers. Plasma elimination half-life ranges from 10 to 28 hours across the population; oral bioavailability is approximately 45 percent owing to substantial first-pass hepatic metabolism.

The compound is well tolerated at the low doses (10 to 50 mg) used for pain and functional gastrointestinal indications but produces dose-dependent anticholinergic (dry mouth, constipation, urinary retention, blurred vision), antihistaminic (sedation, weight gain), and cardiovascular (orthostatic hypotension, tachycardia, QT prolongation, QRS widening) adverse events at the higher doses (100 to 300 mg) used for depression. Amitriptyline has a narrow therapeutic index; ingestion of 10 to 20 mg/kg is potentially life-threatening through sodium channel blockade producing cardiac conduction delay, ventricular dysrhythmias, and myocardial depression. This monograph documents the chemistry, synthesis, and structural class of amitriptyline; the multi-target receptor pharmacology; the comprehensive human pharmacokinetic record including CYP2C19 and CYP2D6 pharmacogenomics; the clinical evidence base across depression, neuropathic pain, migraine, fibromyalgia, irritable bowel syndrome, and other indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five analgesic alternatives (duloxetine, pregabalin, gabapentin, nortriptyline, desipramine) against amitriptyline on five competency standards.